Canaccord Genuity Reiterates Buy Rating on Tempus AI Inc (TEM)

Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $110.00 price target on Tempus AI Inc (NASDAQ: TEM)

The analyst comments "Initiating TEM at BUY with $110 PT. TEM offers oncology testing for genomic profiling, data services and AI applications. In our opinion, the potential of AI deployment at scale in clinical practice could support strong long-term revenue growth for Tempus. TEM's keen acquisition strategy (e.g., Ambry, etc.) could help accelerate growth by providing additional testing and enhancing its AI capabilities. Key assumptions in our DCF model for the company include a 10-year revenue CAGR of 22.8%, peak operating margin of 45.6% and a discount rate of 15.0%."

For an analyst ratings summary and ratings history on Tempus AI Inc click here. For more ratings news on Tempus AI Inc click here.

Shares of Tempus AI Inc closed at $87.78 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Aurora Spine settles patent dispute, secures $600K insider loan